Key Takeaways
- Revenue surged, margins squeezed: Standalone revenue grew 42% YoY on strong API volumes, but raw material inflation and power costs compressed EBITDA margins, and price hikes could not fully catch up.
- Input cost inflation is the dominant story: Solvent prices linked to crude, supply chain disruption, and China lockdowns drove raw material costs up ~25% YoY, and management sees no decline yet.
- Greenfield CAPEX cycle is fully underway: FY23 CAPEX of ₹250-350 crores is earmarked, mostly for two Greenfield sites in Gujarat and Tarapur, with trial production expected by early FY24.
- Regulatory catalysts are approaching: The Tarapur facility cleared an Australian TGA audit and management expects to submit its final US FDA response by August, with an inspection by fiscal year-end.
- What to watch next quarter: Whether raw material prices actually begin to ease, the pace of margin recovery toward the 16% EBITDA target, and any progress on the US FDA import alert clearance.
Revenue Growth Drivers
- API business led the quarter: API revenue grew 46% YoY, with volumes up ~23%, driven by healthy demand in chronic therapies, especially the anti-diabetic segment where recently commissioned capacity is ramping up.
- Formulations gaining export traction: Formulations revenue grew ~11% YoY to ₹69 crores, with exports now contributing 38-40% of segment revenue and carrying substantially higher margins than domestic sales.[9-10]
- Specialty chemicals momentum: The segment grew 28% YoY in FY22, underpinned by niche chemistry skills in chloro sulfonation; a Brownfield expansion commissioned in May 2022 is expected to extend that trajectory.
- Domestic vs export split: Domestic growth of 36-37% in value terms was roughly half volume-driven; export growth of ~50% was about 30-32% from volumes and 18-19% from higher freight rates.
- Chronic therapies expected to outpace acute: Management expects chronic therapy growth to outpace acute, driven by the anti-diabetic capacity addition and the recent launch of gliptins, which have not yet materially contributed to turnover.
Margin Pressure & Recovery Path
- Raw material inflation was the primary drag: Raw material rate variance reached ~25% YoY for the full year, and multiple price hikes taken during the quarter were insufficient because the velocity and volatility of input cost increases remained very high.
- Power and fuel costs added to the squeeze: Higher coal costs compounded the raw material pressure, and the impact flowed through gross margins into EBITDA.
- Gross margin timing lag: Margins on orders negotiated in March were low; for April and May, margins have slightly improved for a few major products, but the impact takes roughly two months to flow through, so Q1 FY23 will carry similar margin pressure.
- Backward integration not yet helping: The Gujarat Greenfield facility has not commenced, and pricing parity issues for basic chemicals between India and China, driven by geopolitics, have added heat on margins.
- Overheads and mix provide partial offsets: Improved product mix in API and operating leverage partially offset the raw material impact; management sees scope to improve overheads by 0.5% to 1%, and the chloro sulfonation plant commissioning will help gross contribution in Q1 and more in Q2.
- Recovery is staged, not sudden: Management called 18% EBITDA by Q2 or Q3 "too optimistic" and set a nearer-term target of 16% by Q2/Q3, with further improvement as newer intermediates are introduced, conditional on input prices easing.
Patil: "18% would be too optimistic but first we will try to achieve that 16% EBITDA margin by Q2, Q3 and then from there onwards, with the introduction of this newer more intermediates, then probably we can look forward to increase it further."
Input Cost & Pricing Environment
- No decline in raw material prices yet: Management stated that raw material prices have not started to come down, though it believes inflation may be near a peak as governments act to control it and commodity-cycle demand softens.
- Price hikes face demand-side limits: While price hikes were taken at the selling end, many formulation customers operate under capped selling prices that increase only ~10% per year, so demand faces some hit when API prices rise faster.
- Chronic vs acute margin dynamics have blurred: Before the macro shocks, chronic products carried structurally higher margins, but the current environment of intermediate price spikes means relative profitability shifts quarter-to-quarter and product-to-product. [11-12]
- China parity is a technology story, not a cost story: Management asserted that on a technological basis, the top-15 products are at par with or better than China; the current margin compression is a temporary, industry-wide phase driven by input prices, not a structural competitiveness gap.
Shah: "Very difficult to give any view, but looks like inflation is at top and all the governments are trying to control inflation, so demand may come down overall on commodities cycle. We expect price to come down by another three to four months, but not at the original level, but it will come down."
CAPEX & Capacity Expansion
- FY23 CAPEX guided at ₹250-350 crores: After sluggish construction activity in H1 FY22, spending is accelerating, with the majority directed to the Gujarat and Tarapur Greenfield projects.
- Two Greenfield sites anchor the pipeline: The Tarapur Greenfield API facility expects trial production by the last quarter of FY23; the Gujarat Greenfield project expects completion by end of FY23 with trial production at the start of FY24.
- Brownfield additions already live: The Tarapur Brownfield specialty chemicals expansion is complete with scale-up batches underway since May 2022, and the chloro sulfonation Brownfield expansion also commenced in May.
- Oncology formulations plant: A new oncology plant for formulations will be commissioned in the coming three months.
- CAPEX split and therapy focus: Excluding ~₹40-50 crores, the remaining FY23 CAPEX is roughly equally divided between Gujarat and Tarapur; spending goes into the derma segment, pharma intermediates, and some animal feed category products.
- Debt-to-equity to peak at 0.7: Greenfield implementation will be funded through a mix of internal accruals and external debt; leverage is expected to decline once projects begin generating revenue.
- PLI scheme deliberately bypassed: The company opted out of the PLI scheme for an intermediate project because it completed the first stage of expansion at a cost far below the government's mandated CAPEX commitment, which management viewed as unnecessary spending.
Patil: "We had requested government that we will implement the same project at the same capacity at a lower cost, but then they said that no, you will need to meet that CAPEX requirement which we thought that unnecessary spending money upfront, there is no point and then apply for the PLI scheme."
Regulatory Catalysts
- US FDA import alert: The Tarapur facility successfully completed a third-party mock audit conducted by ex-US FDA inspectors; the final response is expected to be submitted by early August, with a US FDA inspection anticipated by the end of FY23.
- Australian TGA clearance achieved: The same Tarapur facility cleared an Australian TGA inspection, opening up business expansion in Australia.
- Clearance unlocks multiple markets: If the import alert is lifted, a couple of active ANDA products can begin commercial supply to the US, and the facility's existing EU GMP and CEP approvals mean European market access would also improve materially, since the alert has been an indirect drag there.
- No plans to convert the second facility to US: Management plans to pursue EU-GMP certification for the other, non-US facility but does not intend to convert it into a US-facing facility.
Patil: "There are a lot of indirect benefits in the terms that ... facility also has EU GMP approval and CEP approvals for a few of the big products which we manufacture and we are pretty strong in. So, there are a lot of those products in European market but because of this import alert cracking that market has been little difficult. So, if import alert is cleared, even for the European market from that facility, we can achieve a lot of growth."
Working Capital & Cash Flow
- Operating cash flow was low at ₹70 crores for FY22: The historically high Q4 sale of ~₹697 crores created a large increase in receivables with a cycle of ~90 days, tying up cash.
- Inventory build was strategic: The company deliberately increased raw material inventory to hedge against high inflation and probable supply chain disruptions, and built finished goods inventory in anticipation of a customer pickup in Q1 FY23.
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Raw material price easing | Prices expected to come down, but not to original levels | "Another three to four months" |
| EBITDA margin recovery | Achieve 16% EBITDA margin first, then increase further with new intermediates | Q2/Q3 FY23 |
| US FDA final response submission | Final response to be submitted to US FDA | "Towards end of H1 FY23, most probably by beginning of August" |
| US FDA inspection | Inspection expected at Tarapur facility | "By end of this financial year" (FY23) |
| Tarapur Greenfield trial production | Trial production to begin | Last quarter of FY23 |
| Gujarat Greenfield project completion | Project completion, trial production immediate start of next financial year | End of FY23 / start of FY24 |
| FY23 CAPEX | ₹250-350 crores, majority to Gujarat and Tarapur Greenfield projects | FY23 |
| Debt-to-equity peak | Will go as high as 0.7 during Greenfield implementation | During FY23 implementation phase |
| FY26 revenue target | ₹4,500 crores revenue target | FY26 |
| Long-term EBITDA margin | Aim for near 20% and target crossing 20% once Greenfield projects and regulated markets play out | Post-Greenfield / regulated market entry |
| Formulations revenue | Try to double revenues in three years | Three years |
| Oncology formulations plant | Commissioning | "Coming three months" |
Key Metrics
| Metric | Q4 FY22 |
|---|---|
| Consolidated revenue | ₹697 cr (highest ever quarterly sale), growth of 39% YoY |
| Standalone revenue | ₹642.1 cr, growth of 42% YoY |
| API business revenue growth | 46% YoY |
| Formulations segment revenue | ₹69 cr, growth of approximately 11% YoY |
| Specialty chemicals and intermediates revenue | ₹56 cr, growth of 17% YoY |
| Consolidated EBITDA growth | 9% YoY |
| Consolidated PAT growth | 7% YoY |
| API standalone EBITDA margin | 13.2% |
| Consolidated operating margin | ~12% (per an analyst's math) |
| API volume growth | ~23% YoY |
| Domestic revenue growth | ~37% YoY, 50% of growth from volumes |
| Export revenue growth | ~50% YoY, 30–32% of growth from volumes, 18–19% from freight rate |
| Net debt-to-equity | 0.52x as of March 31, 2022 |
| CAPEX incurred in FY22 | ₹145 cr |
| Planned CAPEX for FY23 | ₹250 cr to ₹350 cr |